You are leaving Evergreentgn.com
You have clicked on an external link and will be taken offsite.
Cancel
Confirm
Lantheus has completed its acquisition of Evergreen Theragnostics, Inc. Please see the
press release
to learn more.
CDMO
Pipeline
Therapeutic Areas
Menu
About us
Facilities
News
Careers
CDMO
Pipeline
Therapeutic Areas
About us
Facilities
News
Careers
menu
Close
News
view details
January 28, 2025
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
view details
October 18, 2024
Evergreen Theragnostics opens CCK2-VIEW, a Phase II small cell lung cancer clinical trial, in the European Union
view details
May 28, 2024
Evergreen Theragnostics announces licensing of EVG321 from Medical University of Innsbruck and enters clinical development of Radioligand Therapies in small cell lung cancer
view details
June 8, 2023
CAM-H2 production at Evergreen marks the expansion of Precirix’ clinical trial to the US
view details
April 3, 2023
Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals
view details
August 18, 2022
Clarity and Evergreen expand Targeted Copper Theranostics manufacturing
view details
March 16, 2022
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
view details
December 1, 2021
MTTI partners with Evergreen to manufacture EvaThera platform of radiopharmaceuticals
view details
October 18, 2021
Evergreen Theragnostics Completes New Jersey Manufacturing Facility
1
...
